Aashka Hospitals (543346)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Latest quarter is profitable: ₹1 Cr net profit on ₹10 Cr sales, implying about a 10% net margin
• Hospital services provide structurally necessary healthcare demand in India
• Small revenue base leaves room for growth if operations stabilise
• Price at the 52-week high shows current market enthusiasm, though not a value signal

Concerns

• Extremely high P/E of 158.05 with profit growth down 82.72%
• Sales down 15.53%, so the business is shrinking rather than expanding
• ROCE of only 4.07% and Piotroski F-Score of 3/9 signal weak capital efficiency and financial strain
• Zero dividend and lack of disclosed book value, debt/equity, and promoter holding data reduce investor protection

AI Analysis

When I see a hospital, I think of a necessary community service, but as an investor I need evidence that the business creates value for owners. Aashka Hospitals does not pass my screen. I am being asked to pay a price-to-earnings ratio of 158.05. That means ₹158 for each rupee of trailing earnings. At the same time, profit has collapsed by 82.72% and sales have fallen by 15.53%. This is the opposite of a strong growth story. The latest quarter shows ₹10 Cr of sales and ₹1 Cr of net profit, so there is some life at the margin. But one good quarter cannot repair a damaged trend. The company earns only 4.07% on capital employed. I can get similar returns without taking business risk. The Piotroski F-Score of 3 out of 9 reinforces my worry that the financial condition is weak. There is no dividend, so I cannot be paid while waiting for a turnaround. The market cap is ₹276 Cr, while the quarterly profit is just ₹1 Cr. At this level, the price is already at the top of its 52-week range, yet the fundamentals are moving in the opposite direction. I also miss basic transparency: no book value, no debt-equity ratio, no promoter holding data in front of me. Graham taught me not to base an investment on hope. This appears to be a very expensive bet on a recovery that has not yet shown up in the numbers. I would rather watch from the sidelines until sales stabilise, margins become repeatable, and returns on capital improve. In the meantime, the 158 P/E gives me no margin of safety. My decision is to pass.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer